검색
Immix Biopharma Inc
IMMX관심 목록에 추가
12.500USD
-0.220-1.73%
종가 09-18 16:00（ET）
891.33M시가총액
손실P/E TTM
자세한 내용은 Immix Biopharma Inc 회사
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Immix Biopharma Inc 프로필
종목 코드 IMMX
회사 이름Immix Biopharma Inc
상장일Dec 16, 2021
CEORachman (Ilya)
직원 수18
유형Ordinary Share
회계 연도 종료Dec 16
주소11400 West Olympic Blvd.
도시LOS ANGELES
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호90064
전화18889581084
웹사이트https://immixbio.com/
종목 코드 IMMX
상장일Dec 16, 2021
CEORachman (Ilya)
Immix Biopharma Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
자주 묻는 질문
Immix Biopharma Inc의 상위 5대 주주는 누구인가요?
Immix Biopharma Inc의 상위 5대 주주는 다음과 같습니다: Mr. Jason Hsu, Ph.D.
Immix Biopharma Inc(IMMX)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Immix Biopharma Inc의 주식을 보유한 기관은 총 105곳이며, 이들이 보유한 주식의 총 가치는 약 24.89M로 전체 발행 주식의 45.75%를 차지합니다. 이는 2025Q4 대비 18028804.00 증가한 수치입니다.